Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Signaturefd LLC

Signaturefd LLC decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 12.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,428 shares of the medical instruments supplier’s stock after selling 354 shares during the period. Signaturefd LLC’s holdings in Becton, Dickinson and Company were worth $592,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Jeppson Wealth Management LLC raised its holdings in Becton, Dickinson and Company by 4.0% in the 3rd quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier’s stock valued at $266,000 after acquiring an additional 40 shares during the last quarter. CX Institutional raised its holdings in Becton, Dickinson and Company by 3.0% in the 3rd quarter. CX Institutional now owns 1,491 shares of the medical instruments supplier’s stock valued at $385,000 after acquiring an additional 43 shares during the last quarter. U.S. Capital Wealth Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 3.4% during the 3rd quarter. U.S. Capital Wealth Advisors LLC now owns 1,310 shares of the medical instruments supplier’s stock worth $339,000 after buying an additional 43 shares during the last quarter. Value Partners Investments Inc. increased its holdings in shares of Becton, Dickinson and Company by 5.2% during the 3rd quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier’s stock worth $225,000 after buying an additional 43 shares during the last quarter. Finally, Atlas Private Wealth Management increased its holdings in shares of Becton, Dickinson and Company by 2.9% during the 3rd quarter. Atlas Private Wealth Management now owns 1,587 shares of the medical instruments supplier’s stock worth $410,000 after buying an additional 45 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.2 %

Becton, Dickinson and Company stock opened at $234.36 on Wednesday. Becton, Dickinson and Company has a fifty-two week low of $229.40 and a fifty-two week high of $287.32. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The firm has a 50 day moving average price of $239.72 and a 200 day moving average price of $241.79. The company has a market capitalization of $67.71 billion, a PE ratio of 55.54, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.73 billion. During the same quarter last year, the firm earned $2.98 EPS. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Research analysts expect that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.31% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on BDX shares. Raymond James raised their price target on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Barclays raised their price target on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.